Price T Rowe Associates Inc. MD Has $10.74 Million Stock Holdings in Inspire Medical Systems, Inc. (NYSE:INSP)

Price T Rowe Associates Inc. MD trimmed its stake in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 64.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 57,932 shares of the company's stock after selling 106,173 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.19% of Inspire Medical Systems worth $10,740,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in INSP. First Horizon Advisors Inc. lifted its position in Inspire Medical Systems by 885.7% in the 4th quarter. First Horizon Advisors Inc. now owns 138 shares of the company's stock worth $26,000 after buying an additional 124 shares in the last quarter. Huntington National Bank increased its stake in shares of Inspire Medical Systems by 228.3% in the fourth quarter. Huntington National Bank now owns 174 shares of the company's stock worth $32,000 after acquiring an additional 121 shares during the last quarter. Harbour Investments Inc. raised its holdings in shares of Inspire Medical Systems by 101.0% during the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company's stock worth $37,000 after acquiring an additional 99 shares in the last quarter. AlphaQuest LLC boosted its position in Inspire Medical Systems by 7,275.0% during the fourth quarter. AlphaQuest LLC now owns 295 shares of the company's stock valued at $55,000 after purchasing an additional 291 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its stake in Inspire Medical Systems by 61.9% in the fourth quarter. Quadrant Capital Group LLC now owns 327 shares of the company's stock valued at $61,000 after purchasing an additional 125 shares in the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CTO John Rondoni sold 583 shares of the company's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the sale, the chief technology officer now owns 10,424 shares of the company's stock, valued at approximately $1,777,187.76. This represents a 5.30 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Shawn Mccormick sold 360 shares of Inspire Medical Systems stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $160.00, for a total transaction of $57,600.00. Following the transaction, the director now directly owns 24,046 shares of the company's stock, valued at $3,847,360. This represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,527 shares of company stock worth $4,851,660. Corporate insiders own 4.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on INSP. Robert W. Baird lifted their price target on Inspire Medical Systems from $230.00 to $236.00 and gave the company an "outperform" rating in a report on Tuesday. JPMorgan Chase & Co. reduced their target price on shares of Inspire Medical Systems from $235.00 to $195.00 and set an "overweight" rating for the company in a research note on Tuesday. Truist Financial cut their price target on shares of Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating on the stock in a report on Tuesday, February 11th. Stifel Nicolaus reduced their price objective on shares of Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating for the company in a research note on Monday, April 21st. Finally, KeyCorp lowered their target price on shares of Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating on the stock in a research report on Monday, April 21st. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $211.91.

Inspire Medical Systems Trading Down 2.1 %

INSP traded down $3.32 on Wednesday, hitting $158.56. 401,702 shares of the stock traded hands, compared to its average volume of 588,359. The business has a fifty day moving average price of $159.46 and a two-hundred day moving average price of $179.13. Inspire Medical Systems, Inc. has a 52 week low of $123.00 and a 52 week high of $256.11. The firm has a market capitalization of $4.72 billion, a PE ratio of 91.79, a P/E/G ratio of 2.86 and a beta of 1.39.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.33. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. The business had revenue of $201.32 million during the quarter, compared to analyst estimates of $194.89 million. During the same period in the prior year, the company posted ($0.34) earnings per share. Inspire Medical Systems's revenue was up 22.7% on a year-over-year basis. On average, equities research analysts forecast that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.